Načítá se...
Treatment of pancreatic cancer—neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is currently ranked fourth place of cancer related mortality. Only a minority of 10–20% of patients with PDAC have a primarily resectable disease, while 50–60% of the patients are diagnosed with irresectable disease. A certain group of patients is defined as “...
Uloženo v:
| Vydáno v: | Transl Gastroenterol Hepatol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AME Publishing Company
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6556697/ https://ncbi.nlm.nih.gov/pubmed/31231699 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tgh.2019.04.09 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|